Mr. Inas Said reports

RISE NANO OPTICS ANNOUNCES FDA CLASS I DEVICE CLASSIFICATION FOR SPECTRAGUARD NANO-OPTIC LENS TECHNOLOGY

Rise Nano Optics Ltd.'s proprietary, patented Spectraguard nano-optic lens technology is Food and Drug Administration registered, and has been classified by the U.S. Food and Drug Administration as a Class I exempt medical device.

The FDA has accepted the company's stated intended use claim for Spectraguard, which is designed to provide eye protection from bright sunlight by filtering 100 per cent of ultraviolet light and up to 90 per cent of wavelengths between 400 and 600 nanometres, including blue light, while preserving natural visual clarity and colour perception.

The FDA registration allows the company to import its products and fully launch its commercialization efforts in the United States following its recent appointment of Erik Ritchie as chief commercial officer. The company is executing a multichannel commercialization strategy with sales targets including eye care professionals, lens manufacturers, optical labs, eyewear brands and direct-to-consumer platforms. The U.S. represents a significant revenue opportunity as one of the largest segments within the global $160-billion (U.S.) eyewear market. In the United States alone, more than 90 per cent of adults use some form of eyewear, highlighting the scale of the addressable market particularly for individuals affected by prolonged screen exposure, light sensitivity and degenerative eye conditions.

"This regulatory milestone represents an important derisking event as we accelerate our commercialization strategy," said Inas Said, founder and chief executive officer of Rise Health. "FDA registration and Class I classification validate the safety profile and intended use of our Spectraguard technology and allow us to continue executing our multipronged commercialization strategy across North America, which includes lens manufacturers, partner labs, eye care professionals and direct-to-consumer channels. I am very proud of this accomplishment for the company and look forward to sharing many more significant milestones as we aim to achieve scale on a global level."

Spectraguard is engineered with a proprietary nano-particle lens architecture that selectively filters high-energy visible light between 400 and 600 nm, including blue light, while preserving natural colour accuracy and visual clarity. By extending protection beyond traditional ultraviolet-only eyewear, the technology is designed to help reduce glare, digital eye strain and long-term vision stress associated with prolonged light exposure. The FDA registration follows the successful completion of biocompatibility testing and complements Rise's growing intellectual property portfolio, which includes multiple patents protecting its nano-material formulations, lens architecture and scalable manufacturing processes.

About Rise Nano Optics Ltd.

Rise Nano trades on the Canadian Securities Exchange under the ticker symbol EYE. Rise is a health technology company specializing in advanced nanotechnology lens solutions designed to selectively filter high-energy visible light wavelengths. Its patented Spectraguard technology integrates nanomaterial innovation, ophthalmic research and scalable optical engineering to serve both clinical and consumer eyewear markets globally.

We seek Safe Harbor.